Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -14.49
- Piotroski Score 2.00
- Grade Buy
- Symbol (INM)
- Company InMed Pharmaceuticals Inc.
- Price $4.37
- Changes Percentage (7.9%)
- Change $0.32
- Day Low $4.02
- Day High $4.56
- Year High $15.70
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.54
- Trailing P/E Ratio -0.44
- Forward P/E Ratio -0.44
- P/E Growth -0.44
- Net Income $-7,675,550
Income Statement
Quarterly
Annual
Latest News of INM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Death row inmate's fate may now lie with East Texas district attorney
The Texas Supreme Court has allowed Robert Roberson's execution to be rescheduled, sparking concern from his attorney Gretchen Sween. The district attorney's decision on rescheduling is awaited, as ne...
By CBS News | 19 hours ago -
Bob Iger's Disney, entertainment firms resume X advertising after...
Big entertainment companies like Disney, Comcast, and Warner Bros. have resumed advertising on Elon Musk's social media platform after a halt due to controversial posts. Spending $3.3 million this yea...
By New York Post | 22 hours ago -
Former Google X employees come out of stealth with TwinMind, an AI app that hears and remembers everything about you
TwinMind, a startup founded by former Google X employees, raised $2.5 million and has a $30 million valuation. The AI assistant app aims to personalize user experiences by constantly learning and reta...
By Business Insider | 1 day ago
